Why it matters: The decision will help people with diabetes who don't have insurance or who face high deductibles and coinsurance rates. However, the amount that health insurers and others will pay Lilly for this insulin, called Lispro, will be about the same as what Lilly gets for Humalog after rebates and discounts — meaning society more broadly will still be paying the same price for this kind of popular insulin.